Guideline for radiotherapy with curative intent in patients with early stage, medically inoperable, non-small cell lung cancer

  • C.B. Falkson Cancer Centre of Southeastern Ontario, Kingston General Hospital and Queen’s University
  • E.T. Vella McMaster University
  • E. Yu London Regional Cancer Centre and Western University
  • M. El-Mallah Durham Regional Cancer Centre
  • R. Mackenzie McMaster University
  • P.M. Ellis Juravinski Cancer Centre; McMaster University
  • Y.C. Ung Sunnybrook Odette Cancer Centre
Keywords: Early-stage disease, inoperable tumours, non-small-cell lung cancer, stereotactic body radiation tyherapy, stereotactic ablative radiation therapy, clinical practice guidelines

Abstract

Objectives

For this guideline, we investigated the effectiveness of radiotherapy with curative intent in medically inoperable patients with early-stage non-small-cell lung cancer (nsclc).

Methods

The guideline was developed by Cancer Care Ontario’s Program in Evidence-Based Care and by the Lung Cancer Disease Site Group through a systematic review of mainly retrospective studies, expert consensus, and formal internal and external reviews.

Recommendations

Stereotactic body radiation therapy (sbrt) with curative intent is an option that should be considered for patients with early-stage, node-negative, medically inoperable nsclc.

Qualifying Statements

  • Because of the high dose per fraction, the planning process and treatment delivery for sbrt require the use of advanced technology to maintain an appropriate level of safety. Consistent patient positioning and 4-dimensional analysis of tumour and critical structure motion during simulation and treatment delivery are essential.
  • Preliminary results for proton-beam therapy have been promising, but the technique requires further clinical study.
Recommended fractionation schemes for sbrt should  result in a biologically effective dose of 100 or greater by  the linear quadric model, choosing an α/β value of 10  [bed10(LQ) ≥ 100].
       
Qualifying Statements
  • Because of the increased risk of treatment-related adverse events associated with centrally located tumours, consideration of tumour size and proximity to critical central structures is required when determining the dose and fractionation.
  • Examples of dose–fractionation schemes used in the included studies have been provided.
  • Based on the current evidence and the opinion of the authors, radiation doses at bed10(LQ) greater than 146 might significantly increase toxicity and should be avoided.
  • Determination of the radiation bed by the linear quadratic model has limitations for the extreme hypofractionated schemes used in sbrt.

Author Biographies

C.B. Falkson, Cancer Centre of Southeastern Ontario, Kingston General Hospital and Queen’s University
Radiation Oncology
E.T. Vella, McMaster University
Cancer Care Ontario, Program in Evidence-Based Care
E. Yu, London Regional Cancer Centre and Western University
Radiation Oncology
M. El-Mallah, Durham Regional Cancer Centre

Radiation Oncology

R. Mackenzie, McMaster University
Cancer Care Ontario, Program in Evidence-Based Care
P.M. Ellis, Juravinski Cancer Centre; McMaster University

Medical Oncology;  Department of Oncology

Y.C. Ung, Sunnybrook Odette Cancer Centre
Radiation Oncology
Published
2017-02-28
How to Cite
Falkson, C., Vella, E., Yu, E., El-Mallah, M., Mackenzie, R., Ellis, P., & Ung, Y. (2017). Guideline for radiotherapy with curative intent in patients with early stage, medically inoperable, non-small cell lung cancer. Current Oncology, 24(1), e44-e49. https://doi.org/10.3747/co.24.3358
Section
Practice Guideline